Table 1.

Trial and Patient Characteristics

Trial	Year of First Accrual	Year of Publication	Total No. of Patients	Follow-Up (years)	Median Age (years)	Induction Regimen	HDC Regimen	Control Regimen	SDI			SDIP
									HDC	Control	Difference	HDC	Control	Difference
MDACC	1990	2000,7 200634	48*	7	46	1,000 F, 50 D, 500 C	5,250 C, 1,200 Et, 165 P over 3 days 2 cycles	No additional chemotherapy	2.32	2.07	0.25	70	50	20
Dutch1	1991	1998,8 200235	81	6	47	500 F, 120 E, 500 C	6,000 C, 480 T, 1,600 Cb over 4 days	No additional chemotherapy	3.13	2.10	1.03	47	25	22
ECOG	1991	20039	540	7	44	1,400 C, 60 D, 1,000 F	6,000 C, 800 T over 4 days	No additional chemotherapy	2.25	2.10	0.15	68	50	18
CALGB	1991	200510	785	9	45	600 C, 60 D, 1,200 F	5,625 C, 165 P, 600 BCNU over 3 days	900 C, 90 P, 90 BCNU over 3 days	2.16	1.90	0.26	52	36	16
MCG	1993	200111	398	7	44	—	7,000 C, 8,000 Mt, 240 E, 600 T, 160-180 A	120 E 3 cycles then 600 C, 40 Mt, 600 F 6 cycles	2.76	1.81	0.95	50	60	−10
NKI	1993	200312	885	8	46	500 F, 90 E, 500 C	6,000 C, 480 T, 1,600 Cb over 4 days	500 F, 90 E, 500 C (1 additional cycle)	2.72	1.70	1.02	49	25	24
GABG	1993	2004,13 200836	302	5	48	90 E, 600 C	6,000 C, 600 T, 40 M over 4 days	1,000 C, 80 Mt, 1,200 F 3 cycles (28 days)	2.23	1.66	0.57	41	40	1
ICCG	1993	200514	281	4	47	cycle 1: 600 F, 50 E, 600 C; cycles 2 and 3: 1,200 F, 50 E, 1200 C	6,000 C, 500 T, 800 Cb	1,200 F, 50 E, 1,200 C 2 additional cycles (28 days)	2.21	1.39	0.82	38	33	5
JCOG	1993	200815	97	7	47	500 C, 40 D, 500 F	6,000 C, 600 T	No additional chemotherapy	1.80	1.56	0.24	43	28	15
SBG	1994	200016 200737	525	6	48	HDC only: 600 C, 60 E, 600 F 3 cycles	6,000 C, 500 T, 800 Cb over 4 days	Doses individually tailored, 6 plans. Start dose: 600 F, 75 E, 900 C, 9 cycles (21 days)	2.33	1.86	0.47	35	50	−15
PEGASE 01	1994	200517	314	5	48	500 F, 100 E, 500 C	120 mg/kg C, 45 M, 140 A	No additional chemotherapy	2.98	1.82	1.16	54	22	32
WSG	1995	200518	403	5	49	90 E, 600 C	3,000 C, 90 E 400 T every 28 days	600 C, 40 Mt, 600 F 3 cycles (14 days)	2.78	2.10	0.68	33	29	4
ACCOG	1995	200419	605	6	45	75 D	4,000 C single dose then 6,000 C, 800 T over 4 days	600 C, 50 Mt, 600 F 8 cycles (21 days)	2.48	1.62	0.86	47	58	−11
IBCSG	1995	2006,20 200938	344	5	47	—	4,000 C, 200 E 3 cycles (21 days)	600 C, 90 E or 60 D 4 cycles (21 days), then 1,400 C, 1,200 F, 80 Mt over 14 days 3 cycles (28 days)	4.73	1.84	2.89	42	44	−2
SWOG	1996	200721	602	8	46	HDC only: 80 D, 600 C	STAMP I: C, P, BCNU or STAMP V: C, Cb, T	80 D: 3 cycles (14 days) then 200 Pac: cycles (14 days) then 3,000 C 3 cycles (14 days)	3.00	2.50	0.50	36	45	−9
Total			6,210	7					2.66	1.87	0.79	47	39.7	7.3

Abbreviations: A, melphalan; ACCOG, Anglo-Celtic Cooperative Oncology Group; BCNU, carmustine; C, cyclophosphamide; CALGB, Cancer and Leukemia Group B; Cb, carboplatin; D, doxorubicin; E, epirubicin; ECOG, Eastern Cooperative Oncology Group; Et, etoposide; F, fluorouracil; GABG, German Adjuvant Breast Cancer Study Group; HDC, high-dose chemotherapy; IBCSG, International Breast Cancer Study Group; ICCG, International Collaborative Cancer Group; JCOG, Japan Clinical Oncology Group; M, mitoxantrone; MCG, Michelangelo Cooperative Group; MDACC, MD Anderson Cancer Center; Mt, methotrexate; NKI, the Netherlands Cancer Institute; P, cisplatin; Pac, paclitaxel; PEGASE01, Programme d'évalution des greffes autologues dans le cancer du sein; SBG, Scandinavian Breast Group; SDI, summation dose intensity; SDIP, summation dose intensity product; STAMP I, Solid Tumor Autologous Marrow Transplant Program regimen I (C 1.85 g/m²/d and P 55 mg/m²/d, each for 3 days [days −6, −5, and −4], followed by BCNU 600 mg/m² [day−³]); STAMP V, Solid Tumor Autologous Marrow Transplant Program regimen V (C 1.5 g/m²/d, Cb 200 mg/m²/d, and T 125 mg/m²/d for 4 days (days −7 through −4); SWOG, Southwest Oncology Group; T, thiotepa; WSG, West German Study Group.

^*Of the 78 total patients enrolled on this trial, 30 were randomly assigned to receive neoadjuvant therapy rather than adjuvant therapy; these patients were not included in the meta-analysis.